Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Abstract: The wearable article (11) comprises a power source (111) and a processor (112). The processor (112) determines whether a power transfer condition is satisfied. In response, the processor (112) is arranged to control the wearable article (11) to transfer power from the power source (111) to an electrical load of an external apparatus. The wearable article (11) may comprise an interface element (114) for forming an electrical connection with the externa apparatus. The wearable article (11) may comprise a power transmitter (113) for beaming electromagnetic energy to the external apparatus. The wearable article (11) may be a garment.

Abstract: The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Abstract: An image of a garment is obtained (101). The garment comprises a marker located on an outside surface of the garment. The marker comprises a code string identifying the garment encoded into a visual symbol. The image is processed to generate a data string representing the visual symbol (102). The data string is used to access activity data associated with a sensor of the garment identified by the code string. The system comprises the garment and one or more electronic devices operable to perform the method.

Abstract: The method comprises receiving a representation of a visual symbol, wherein the visual symbol comprises a code string identifying the garment that is encoded into the visual symbol (101). The method comprises establishing, based on the representation of the visual symbol, the identity of the garment (102). The method comprises transmitting, to the identified garment, an authorisation code to activate a sensor of the garment to record activity data (103).

Abstract: The method comprises receiving a representation of a visual symbol, wherein the visual symbol comprises a code string identifying the garment that is encoded into the visual symbol (101). The method comprises establishing, based on the representation of the visual symbol, the identity of the garment (102). The method comprises transmitting, to the identified garment, an authorisation code to activate a sensor of the garment to record activity data (103).

Abstract: The wearable article (11) comprises a power source (111) and a processor (112). The processor (112) determines whether a power transfer condition is satisfied. In response, the processor (112) is arranged to control the wearable article (11) to transfer power from the power source (111) to an electrical load of an external apparatus. The wearable article (11) may comprise an interface element (114) for forming an electrical connection with the externa apparatus. The wearable article (11) may comprise a power transmitter (113) for beaming electromagnetic energy to the external apparatus. The wearable article (11) may be a garment.

Abstract: The method comprises obtaining a first source of authentication information for the user comprising a feature set extracted from biometric data sensed by sensors of the wearable device (S101). The extracted feature set is input into a recognition algorithm which uses the extracted feature set and predetermined feature set representing an authorised user that is authorised to use the wearable device, and generates a confidence level indicating the likelihood that the user wearing the wearable device is the authorised user (S102). A second source of authentication information is obtained from the user (S103). The method identifies, from the second source of authentication information, whether the user is authorised to use the wearable device (S104). If the user is authorised, the method authenticates the identity of the user wearing the wearable device as corresponding to the authorised user (S105).

Abstract: The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.

Abstract: The wearable device (10) comprises a liveness detection module (103) arranged to detect whether the wearable device (10) is being worn by a user. The wearable device (10) comprises an activation message module (105) arranged to generate an activation message for requesting that wireless network services be activated for the wearable device (10) in response to the liveness detection module detecting that the wearable device is being worn. The wearable device (10) comprises a communicator (107) arranged to transmit the activation message to a server operable to activate wireless network services for the wearable device (10). The wireless network services are to be activated for a first wireless network. The communicator (107) is arranged to transmit the activation message via a second wireless network that the wearable device (10) is activated to transmit data on.

Abstract: A controller (161) for a device (16) comprises an identifier obtaining module (165) arranged to obtain an identifier for a garment worn by a user. The controller (161) comprises a biometric module (167) arranged to use the identifier to obtain a biometric identity for the user wearing the identified garment and determine an operational mode for the device (16) from the biometric identity. A command generation module (169) is operable to generate a control command for controlling the device (16) based on the operational mode. The biometric module (167) may determine whether the user identified by the biometric identity is authorised to operate the device (16). The control command may be generated based on this determination.

Abstract: The wearable device (10) comprises a liveness detection module (103) arranged to detect whether the wearable device (10) is being worn by a user. The wearable device (10) comprises a communicator (107) arranged to transmit a message to a server in response to the liveness detection module (103) detecting that the wearable device (10) is being worn. Prior to the liveness detection module (103) detecting that the wearable device (10) is being worn by a user, the wearable device (10) is arranged to operate in a low power mode.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.

Abstract: An image of a garment is obtained (101). The garment comprises a marker located on an outside surface of the garment. The marker comprises a code string identifying the garment encoded into a visual symbol. The image is processed to generate a data string representing the visual symbol (102). The data string is used to access activity data associated with a sensor of the garment identified by the code string. The system comprises the garment and one or more electronic devices operable to perform the method.

Abstract: The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Abstract: The method comprises receiving a representation of a visual symbol, wherein the visual symbol comprises a code string identifying the garment that is encoded into the visual symbol (101). The method comprises establishing, based on the representation of the visual symbol, the identity of the garment (102). The method comprises transmitting, to the identified garment, an authorisation code to activate a sensor of the garment to record activity data (103).

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.